Roger Nitsch
32Patents
9h-index
46Co-inventors
75Inventor score
Filing activity: Apr 15, 1994 → May 28, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8940272B2 | Human anti-tau antibodies | Physics | 27 | Active |
| US8906367B2 | Method of providing disease-specific binding molecules and targets | Chemistry; Metallurgy | 18 | Active |
| US8940276B2 | Human anti-alpha-synuclein antibodies | Physics | 17 | Active |
| US5631168A | Antemortem diagnostic test for Alzheimer's disease | Physics | 17 | Expired |
| US5545566A | Antemortem diagnostic test for alzheimer's disease | Physics | 12 | Expired |
| US9670272B2 | Method of providing disease-specific binding molecules and targets | Physics | 11 | Active |
| US9828420B2 | Method of providing disease-specific binding molecules and targets | Physics | 11 | Active |
| US9605059B2 | Human anti-tau antibodies | Physics | 10 | Active |
| US5962463A | Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein | Physics | 9 | Expired |
| US9580493B2 | Anti-α synuclein binding molecules | Physics | 8 | Active |
| US10131708B2 | Methods of treating Alzheimer's disease | Physics | 8 | Active |
| US6329155A | Methods of identifying agents which regulate release of amyloid precursor protein | Emerging Cross-Sectional Technologies | 7 | Expired |
| US9896504B2 | Human anti-alpha-synuclein antibodies | Physics | 6 | Active |
| US10202445B2 | Method of providing disease-specific binding molecules and targets | Physics | 6 | Active |
| US6573276B2 | Muscarinic M1 agonist as an inhibitor of beta-amyloid (A&bgr;40 and A&bgr;42)-synthesis | Human Necessities | 5 | Expired |
| US8022268B2 | Transgenic animal model for alzheimer's disease | Chemistry; Metallurgy | 5 | Active |
| US10259866B2 | TDP-43 specific binding molecules | Physics | 4 | Active |
| US10874725B2 | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders | Emerging Cross-Sectional Technologies | 3 | Active |
| US9283271B2 | Human anti-SOD1 antibodies | Physics | 3 | Active |
| US9587014B2 | TDP-43 specific binding molecules | Physics | 3 | Active |
| US9370531B2 | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders | Emerging Cross-Sectional Technologies | 3 | Active |
| US10301381B2 | Anti-alpha synuclein binding molecules | Physics | 2 | Active |
| US9975947B2 | Anti-alpha synuclein binding molecules | Physics | 2 | Active |
| US10344097B2 | Human anti-SOD1 antibodies | Physics | 1 | Active |
| US8323647B2 | Humanized antibodies against the β-amyloid peptide | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.